This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Hepatocellular Carcinoma (HCC)_Torisel_

This study has been completed.
Information provided by (Responsible Party):
CCTU, Chinese University of Hong Kong Identifier:
First received: December 1, 2010
Last updated: September 27, 2016
Last verified: January 2016
This is a phase I/II study to evaluate dose limited toxicity and efficacy of Torisel

Condition Intervention Phase
Inoperable HCC Drug: Torisel Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression

Resource links provided by NLM:

Further study details as provided by CCTU, Chinese University of Hong Kong:

Primary Outcome Measures:
  • • To establish the maximum tolerated dose (MTD) and a suitable dose for Phase II evaluation of Torisel® given as a weekly dose in patients with advanced hepatocellular carcinoma (HCC) [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • • To determine and establish the safety and toxicity profile of Torisel® and to identify any dose limiting toxicities (DLTs) in advanced HCC [ Time Frame: 2 Years ]
  • • To determine progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) treated with Torisel® [ Time Frame: 4 Years ]
  • • To correlate stathmin expression in pre-treatment HCC tumour biopsies and clinical response to Torisel® [ Time Frame: 2 years ]
  • • To determine the response rate (CR and PR) based on RECIST criteria [ Time Frame: 2 years ]
  • • To determine clinical benefit rate (CBR, percent of patients experiencing CR, PR or SD ≥ 12 weeks) [ Time Frame: 2 years ]
  • • To determine duration of response (DR) [ Time Frame: 2 years ]
  • • To determine overall survival (OS) [ Time Frame: 4 years ]

Enrollment: 46
Study Start Date: October 2009
Study Completion Date: January 2016
Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Torisel Drug: Torisel
Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed hepatocellular carcinoma that is not amenable to curative resection
  • measurable disease
  • Age >=18 years.
  • Life expectancy of greater than 12 weeks.
  • ECOG performance status <= 2
  • Prior systemic therapy for HCC is allowed
  • Adequate haematologic, renal and hepatic function
  • Absence of cirrhosis or Child's A cirrhosis
  • Fasting total cholesterol <9.1 mmol/liter and fasting triglyceride level <4.5 mmol/liter)

Exclusion Criteria:

  • Patients who have had systemic therapy or radiotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.
  • Patients receiving any other investigational agents concurrently.
  • Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • Uncontrolled intercurrent diseases such as, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01251458

Hong Kong
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
Sponsors and Collaborators
Chinese University of Hong Kong
Principal Investigator: Winnie Yeo, MD, FRCP Department of Clinical Oncology, The Chinese University of Hong Kong
  More Information

Responsible Party: CCTU, Comprehensive Clinical Trial Unit, Chinese University of Hong Kong Identifier: NCT01251458     History of Changes
Other Study ID Numbers: HCC022
Study First Received: December 1, 2010
Last Updated: September 27, 2016

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents processed this record on June 23, 2017